ReviewJournal of molecular medicine (Berlin, Germany)2025
Application of mesenchymal stem cells in ferroptosis-related diseases.
Review in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern medicine has achieved groundbreaking advancements in disease diagnosis and treatment, yet significant challenges remain in managing conditions such as age-related diseases, tumors, autoimmune disorders, and neurological conditions. Conventional drug therapies often suffer from inadequate targeting, severe toxic side effects, and limited therapeutic efficacy, leading to adverse clinical outcomes such as disease recurrence and organ dysfunction. In recent years, mesenchymal stem cells (MSCs) have demonstrated transformative potential in regenerative medicine and disease therapy. Leveraging their multipotent differentiation potential, immunomodulatory properties, and paracrine functions, MSCs offer innovative strategies by enhancing tissue repair and microenvironmental homeostasis. Notably, ferroptosis-a newly identified form of regulated cell death-has emerged as a critical research frontier. MSCs and their exosomes exhibit a remarkable ability to modulate ferroptosis by regulating iron ions and lipid peroxide levels. This review provides an in-depth analysis of the molecular pathways through which MSCs influence ferroptosis. Additionally, it explores recent advances in ferroptosis regulation in transplanted MSCs, shedding light on their clinical applicability. In summary, this work underscores the therapeutic promise of MSCs in treating ferroptosis-associated diseases.
Indexed as
Identifiers
40900155What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.